Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1073 - 1080 of 12141 results
The Plan Sponsor's Guide to Drug Formularies and Prior Authorizations
March 25, 2024| News
Mintz Sees Revenue Hit All-Time High
March 25, 2024| News
Health Law Diagnosed – Women Leaders in Health Care: The Emerging Role of AI in Health Care
March 22, 2024| Podcast| Viewpoint
Energy & Sustainability Washington Update — April 2024
March 22, 2024| News
EPA Requires Industrial Sites to Plan for Pollution from Floods
March 22, 2024| News
Health Care Roundtable: Current Trends in State Health Care Transaction Review and What to Expect in 2024
March 21, 2024| Webinar| Viewpoint
FTC Chair Khan: “We Need to Choose Competition over National Champions” in the AI Age — AI: The Washington Report
March 21, 2024| Article| Viewpoint
EnforceMintz — Health Care False Claims Act Statistical Year in Review
March 20, 2024| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|